Will Tariffs on Pharma Imports Lead to Drug Shortages?

The Trump administration’s investigation into pharmaceutical imports could lead to tariffs on both finished drugs and active pharmaceutical ingredients (APIs). Given that generics constitute approximately 90% of US prescriptions and often rely on imported APIs, these tariffs on pharma may strain supply chains and increase costs.

Experts warn that manufacturers with slim profit margins might reduce production or withdraw from the market, exacerbating existing shortages. In early 2024, the US faced over 300 active drug shortages, including critical medications like chemotherapy agents and antibiotics.

This poll seeks to gauge industry sentiment on whether such tariffs on pharma could further impact the availability of generics.

Related: P​harma Tariffs Update: 90 Day Reprieve for Most Except China